Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022. “With positive top-line results having been reported for IMerge...
